{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:10:07Z","timestamp":1756311007424,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Immune checkpoint inhibitors have become the cornerstone in the management of a variety of cancers and have been implicated in immune-related rheumatological adverse events, including inflammatory myositis, polyarthritis and vasculitis. Existing literature has documented large vessel vasculitis in association with ipilimumab, pembrolizumab and nivolumab therapy. Although large vessel vasculitis was reported in one patient who had received both atezolizumab and pegfilgrastim, our patient represents the first instance of large vessel vasculitis associated with atezolizumab alone. Discontinuation of atezolizumab and tapered glucocorticoid therapy resulted in clinical and radiographic resolution.<\/jats:p>","DOI":"10.1136\/bcr-2024-263324","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:05:15Z","timestamp":1745449515000},"page":"e263324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Large vessel vasculitis associated with atezolizumab"],"prefix":"10.1136","volume":"18","author":[{"given":"Prathyusha","family":"Chennupati","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Overlook Medical Center, Summit, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Pianin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Overlook Medical Center, Summit, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Kramer","sequence":"additional","affiliation":[{"name":"Institute for Rheumatic & Autoimmune Diseases, AMG Rheumatology\/Overlook Medical Center, Summit and Morristown, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4615","authenticated-orcid":false,"given":"Elliot D","family":"Rosenstein","sequence":"additional","affiliation":[{"name":"Institute for Rheumatic & Autoimmune Diseases, AMG Rheumatology\/Overlook Medical Center, Summit and Morristown, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025082708424744000_18.4.e263324.1","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2732408","article-title":"Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies","volume":"2018","author":"Magalh\u00e3es","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2025082708424744000_18.4.e263324.2","first-page":"1","article-title":"Rapidly Progressive Pauci-Immune Glomerulonephritis with Aberrant Fibrinoid Necrosis Associated with Atezolizumab, an Immune Check Point Inhibitor: A Case Report and Review of Literature","volume":"12","author":"Nikolopoulos","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"2025082708424744000_18.4.e263324.3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2169\/internalmedicine.2343-23","article-title":"IgA Vasculitis during Atezolizumab Treatment","volume":"63","author":"Ono","year":"2024","journal-title":"Intern Med"},{"key":"2025082708424744000_18.4.e263324.4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdcr.2023.09.042","article-title":"A case of urticarial vasculitis associated with atezolizumab","volume":"43","author":"Young","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2025082708424744000_18.4.e263324.5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892"},{"key":"2025082708424744000_18.4.e263324.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2648"},{"key":"2025082708424744000_18.4.e263324.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025082708424744000_18.4.e263324.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321"},{"key":"2025082708424744000_18.4.e263324.9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.arcmed.2021.09.004","article-title":"Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors","volume":"53","author":"Cano-Cruz","year":"2022","journal-title":"Arch Med Res"},{"key":"2025082708424744000_18.4.e263324.10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00024.2017"},{"key":"2025082708424744000_18.4.e263324.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616848114"},{"key":"2025082708424744000_18.4.e263324.12","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1291","article-title":"Large-vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small-cell lung cancer","volume":"12","author":"Shiraha","year":"2024","journal-title":"Respirol Case Rep"},{"key":"2025082708424744000_18.4.e263324.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.02.013"},{"key":"2025082708424744000_18.4.e263324.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4177-0"},{"key":"2025082708424744000_18.4.e263324.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-019-0828-7","article-title":"Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review","volume":"21","author":"Crout","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2025082708424744000_18.4.e263324.16","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7971169","article-title":"A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab","volume":"2022","author":"Bloomer","year":"2022","journal-title":"Case Reports Immunol"},{"key":"2025082708424744000_18.4.e263324.17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CJI.0000000000000394","article-title":"Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy","volume":"45","author":"Berry","year":"2022","journal-title":"J Immunother"},{"key":"2025082708424744000_18.4.e263324.18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaophthalmol.2018.5191","article-title":"Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis","volume":"137","author":"Emens","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2025082708424744000_18.4.e263324.19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database","volume":"13","author":"Kato","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:42:53Z","timestamp":1756309373000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bcr-2024-263324"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263324","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}